Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Preimplantation Genetic Testing Market analysis

The UK Preimplantation Genetic Testing Market was valued at $35.1 Million in 2025 and projected to reach to $62.8 Million by 2030, representing a compound annual growth rate of 12.3%. The UK preimplantation genetic testing market is positioned for sustained growth through 2030, driven by rising infertility rates, increased consumer demand for genetic screening, and expanding clinic capacity.

UK Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Preimplantation Genetic Testing Market Trends and Insights

  • The UK market is driven by increasing adoption of assisted reproductive technologies, growing awareness of genetic screening benefits, and supportive regulatory frameworks that facilitate PGT accessibility across fertility clinics.
  • The UK's advanced healthcare infrastructure and strong emphasis on reproductive medicine position it as a key European hub for genetic testing innovation. In the UK, demand for PGT is accelerating due to rising maternal age, heightened consumer preference for genetic risk assessment, and expanding NHS coverage considerations.
  • The UK market benefits from established clinical guidelines and a mature fertility sector that integrates PGT into standard practice.
  • Between 2025 and 2030, the UK is expected to see continued investment in genomic technologies and laboratory capacity, supporting the projected 12.3% compound annual growth rate and market expansion to nearly $63 million..

Key Market Statistics

  • CAGR (2025-2030) 12.3% CAGR
  • Market Size, 2025 ~USD 35.1 Million
  • Forecast, 2030 ~USD 62.8 Million
  • Country UK

UK Preimplantation Genetic Testing Market Overview

Market Valuation Growth :

The UK preimplantation genetic testing market is valued at $35.1 million in 2025, with a projected CAGR of 12.3% through 2030, reaching $62.8 million. This growth rate outpaces the global average of 10.5%, indicating strong regional momentum.

Regulatory Support & Accessibility :

The UK benefits from supportive regulatory frameworks and established guidelines from the Human Fertilisation and Embryology Authority (HFEA), which facilitate PGT accessibility across fertility clinics and drive standardized adoption of genetic screening technologies.

Rising ART Adoption :

Increasing adoption of assisted reproductive technologies (ART) across UK fertility centers is a primary growth driver. Enhanced patient awareness of genetic screening benefits and improved success rates are encouraging more couples to pursue PGT-enabled IVF treatments.

Clinical Integration & Innovation :

UK fertility clinics are increasingly integrating advanced PGT methodologies, including PGT-A, PGT-M, and PGT-SR. Growing investment in genomic infrastructure and partnerships between private and NHS-affiliated centers are accelerating market expansion.

UK Preimplantation Genetic Testing Market Dynamics

  • The regulatory environment established by the HFEA continues to support innovation while maintaining safety standards, creating a favorable landscape for market participants. Key growth catalysts include enhanced reimbursement discussions, growing public awareness campaigns, and technological advancements reducing PGT costs.
  • As more UK fertility centers adopt PGT protocols and patient education improves, market penetration is expected to deepen, particularly among younger demographic cohorts seeking proactive genetic health management..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • The UK PGT market is valued at $35.1 million in 2025 and will grow to $62.8 million by 2030, representing a 12.3% CAGR.
      • The UK benefits from advanced healthcare infrastructure, established clinical guidelines, and a mature fertility sector that supports widespread PGT adoption.
      • Rising maternal age, increased genetic risk awareness, and potential NHS coverage expansion are key growth drivers in the UK market.
      • The UK is positioned as a leading European hub for PGT innovation, with continued investment in genomic technologies and laboratory capacity expected through 2030.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      UK Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      UK: PREIMPLANTATION GENETIC TESTING MARKET, BY END USER, 2023–2030

      Segment20232024202520262027202820292030CAGR (%)
      DIAGNOSTIC LABORATORIES66.67.38.29.310.511.913.613.1
      FERTILITY CLINICS17.118.820.723.125.929.232.937.212.4
      HOSPITALS4.34.75.15.66.377.88.711.4
      OTHER END USERS1.71.822.12.42.62.93.210.7
      TOTAL29.131.835.139.143.849.355.562.812.3

      Target Audience

      • Fertility Clinic Operators : UK-based fertility clinics and reproductive medicine centers need market data to assess PGT service expansion opportunities, benchmark against competitors, and understand patient demand trends to optimize service offerings and capital allocation.
      • Diagnostic Laboratory Providers : Genetic testing laboratories and genomic service providers require UK-specific market insights to identify growth opportunities, evaluate clinic partnerships, and develop targeted marketing strategies for PGT service expansion in the region.
      • Medical Device & Technology Companies : PGT technology vendors and equipment manufacturers need UK market analysis to assess adoption rates, identify key clinic accounts, understand regulatory requirements, and develop go-to-market strategies for genetic testing platforms.
      • Healthcare Investors & PE Firms : Investment firms evaluating UK fertility and reproductive health opportunities require detailed market sizing, growth projections, and competitive analysis to identify acquisition targets and assess portfolio company expansion potential.
      • Healthcare Policy & Regulatory Bodies : NHS trusts, HFEA officials, and healthcare policymakers need market intelligence to inform reimbursement policies, regulatory frameworks, and strategic planning for genetic testing accessibility and equitable service distribution across the UK.

      Key Companies in the UK Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • UK-Specific Market Sizing : Access precise valuation data for the UK market ($35.1M in 2025) with country-specific CAGR projections (12.3%) and 2030 forecasts ($62.8M), enabling accurate business planning and investment decisions tailored to the UK landscape.
      • Regulatory & Compliance Insights : Understand the UK's unique regulatory environment shaped by HFEA guidelines and NHS integration. Gain clarity on compliance requirements, reimbursement pathways, and licensing standards specific to UK fertility providers and diagnostic laboratories.
      • Competitive Landscape Analysis : Identify key UK market players, clinic networks, and diagnostic service providers. Benchmark competitive positioning, market share distribution, and differentiation strategies among established and emerging PGT service providers in the UK.
      • Growth Driver Identification : Discover region-specific growth catalysts including NHS partnership opportunities, private clinic expansion trends, patient demographic shifts, and emerging clinical applications driving PGT adoption across UK fertility centers.
      • Strategic Investment Guidance : Make informed investment and expansion decisions with UK market intelligence. Evaluate clinic acquisition targets, technology partnerships, and service expansion opportunities aligned with the 12.3% CAGR growth trajectory through 2030.

      Frequently asked questions

      What is the current size of the UK preimplantation genetic testing market?

      The UK PGT market is valued at $35.1 million in 2025 and is projected to reach $62.8 million by 2030, growing at a 12.3% CAGR.

      What factors are driving growth in the UK PGT market?

      Key drivers in the UK include rising maternal age, increased awareness of genetic screening benefits, supportive regulatory frameworks, advanced healthcare infrastructure, and potential NHS coverage expansion.

      How does the UK PGT market compare to other European markets?

      The UK is positioned as a leading European hub for PGT due to its mature fertility sector, established clinical guidelines, advanced genomic capabilities, and strong regulatory support for genetic testing services.

      What is the forecast growth rate for the UK PGT market through 2030?

      The UK PGT market is expected to grow at a compound annual growth rate of 12.3% from 2025 to 2030, driven by technological advancement and increased clinical adoption.

      Which segments are contributing most to UK PGT market expansion?

      Growth in the UK is supported by increased adoption of assisted reproductive technologies, expanded laboratory capacity, rising demand for genetic risk assessment, and integration of PGT into standard fertility practice.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status